WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient

(2010) Yusuke Oji et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects

(2010) Yoshihiro Oka et al.   Immunotherapy

WT1 peptide immunotherapy for cancer in children and young adults

(2010) Yoshiko Hashii et al.   PEDIATRIC BLOOD & CANCER

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

(2009) I. Vergote et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

(2008) Shuichi Izumoto et al.   JOURNAL OF NEUROSURGERY